ClinicalTrials.gov
public full text
Public Domain
Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism
This placebo-controlled study is designed to evaluate the efficacy of glycine, an agonist of the glycine-B co-agonist site of the NMDA receptor, on alcohol consumption and craving as well as negative symptoms in schizophrenia. Glycine will decrease the rewarding action of ethanol and reduce ethanol consumption. Also, glycine will improve negative symptoms and cognitive deficits in schizophrenia.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Glutamate, Learning, and Working Memory#1059820
- Group Differences of Multiregion Glutamate Concentration in Clinical High Risk and Schizophrenia.#362079
- Minocycline and Tobacco Craving in Smokers With Schizophrenia#911878
- N-methylglycine (Sarcosine) Treatment for Depression#914050
- Efficacy and Safety of Quetiapine Fumarate in the Treatment of Schizophrenic Patients#1029920
Record · ID 980298
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive